Compounded tirzepatide is the same dual GIP/GLP-1 receptor agonist as Mounjaro and Zepbound, prepared by a 503A pharmacy instead of Eli Lilly. The molecule is identical. The active mass per dose is identical. What differs is the vial concentration and the regulatory state.
Eli Lilly removed Mounjaro and Zepbound from the FDA drug shortage list in late 2024, narrowing the legal window for 503A compounding. As of May 2026, some 503A pharmacies still compound under medical-necessity criteria. 503B bulk compounding is banned. Confirm legal status with your prescriber and pharmacy before each refill.
Tirzepatide's 6× dose range (2.5–15 mg) creates a pharmacy-side trade-off that semaglutide's 10× tighter range (0.25–2.4 mg) doesn't: pick a concentration high enough that 15 mg fits a single syringe draw, low enough that 2.5 mg isn't a microliter draw. Most pharmacies target 15–30 mg/mL. If yours doesn't, the calculator above will catch the mismatch before you draw the wrong volume.
Discontinuation rose from ~1.4% at 2.5 mg to ~7% at 5 mg in SURMOUNT-1 (NEJM 2022) — the 5 mg step is the most common drop-off point. Holding 5 mg for an extra 4 weeks before advancing to 7.5 mg is a defensible move; the FDA label specifies minimum, not maximum, hold times.